Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Midwest Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,466,535

303 payments

Through program year 2025, Midwest Clinical Research LLC is reported as receiving $1,466,535 in research payments, across 303 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $571,656 69
2024 Research $500,938 71
2023 Research $153,513 52
2022 Research $84,622 35
2021 Research $76,405 34
2020 Research $25,202 19
2019 Research $54,199 23

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $468,314 106 payments
  2. Chiesi USA, Inc. $362,186 66 payments
  3. Eli Lilly and Company $244,983 2 payments
  4. Teva Pharmaceuticals USA, Inc. $142,304 36 payments
  5. Vanda Pharmaceuticals Inc. $64,831 20 payments
  6. Regeneron Pharmaceuticals, Inc. $47,603 27 payments
  7. Pfizer Inc. $42,184 6 payments
  8. Hoffmann-La Roche Limited $41,313 14 payments
  9. Verona Pharma, Inc. $19,431 3 payments
  10. Sanofi US Services Inc. $17,202 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. PH Iib of Astegolimab in COPD $252,853 71 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ Ly3650150 in Adult Participants With Perennial Allergic Rhinitis $244,983 2 payments
  3. Ph III OLE of Astegolimab in COPD $214,823 28 payments
  4. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $197,736 21 payments
  5. A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $142,100 35 payments
  6. Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis $64,831 20 payments
  7. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $54,755 14 payments
  8. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $53,240 6 payments
  9. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis $46,977 25 payments
  10. Phase 3B4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor TNF Inhibitor in Subjects With Rheumatoid Arthritis $42,184 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record